share_log

Recursion Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Khan Najat

Recursion Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Khan Najat

Recursion Pharmaceuticals | 3：首次持股声明-董事 Khan Najat
美股sec公告 ·  04/25 17:11
Moomoo AI 已提取核心信息
Recursion Pharmaceuticals, Inc. (Recursion), a biotechnology firm trading under the ticker RXRX, has reported an initial statement of beneficial ownership of securities filed by director Najat Khan. The SEC Form 3, filed on April 23, 2024, indicates that Khan does not beneficially own any securities in the company. The form, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, was submitted following an event on April 16, 2024. The document was signed by Jonathan Golightly, attorney-in-fact, and confirms Khan's status as a director and a 10% owner of the issuer. This filing is part of the regulatory requirements that track the ownership of securities by corporate insiders, providing transparency for investors regarding the holdings of key company officials.
Recursion Pharmaceuticals, Inc. (Recursion), a biotechnology firm trading under the ticker RXRX, has reported an initial statement of beneficial ownership of securities filed by director Najat Khan. The SEC Form 3, filed on April 23, 2024, indicates that Khan does not beneficially own any securities in the company. The form, which is a requirement under Section 16(a) of the Securities Exchange Act of 1934, was submitted following an event on April 16, 2024. The document was signed by Jonathan Golightly, attorney-in-fact, and confirms Khan's status as a director and a 10% owner of the issuer. This filing is part of the regulatory requirements that track the ownership of securities by corporate insiders, providing transparency for investors regarding the holdings of key company officials.
股票代码为RXRX的生物技术公司Recursion Pharmicals, Inc.（Recursion）报告了董事纳贾特·汗提交的初步证券实益拥有权声明。美国证券交易委员会于2024年4月23日提交的表格3表明，汗不以实益方式拥有该公司的任何证券。该表格是1934年《证券交易法》第16（a）条的要求，是在2024年4月16日的一次活动之后提交的。该文件由事实律师乔纳森·戈莱特利签署，证实了汗的董事身份和发行人10％的所有者。该文件是追踪公司内部人士证券所有权的监管要求的一部分，为投资者提供了有关公司主要官员持股情况的透明度。
股票代码为RXRX的生物技术公司Recursion Pharmicals, Inc.（Recursion）报告了董事纳贾特·汗提交的初步证券实益拥有权声明。美国证券交易委员会于2024年4月23日提交的表格3表明，汗不以实益方式拥有该公司的任何证券。该表格是1934年《证券交易法》第16（a）条的要求，是在2024年4月16日的一次活动之后提交的。该文件由事实律师乔纳森·戈莱特利签署，证实了汗的董事身份和发行人10％的所有者。该文件是追踪公司内部人士证券所有权的监管要求的一部分，为投资者提供了有关公司主要官员持股情况的透明度。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息